Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

View Full Paper
Ask AI
Bookmark
Share

Authors

VSValeria SantiniAzienda Ospedaliero-Universitaria CareggiMSMichael R. SavonaVanderbilt UniversityMDMaría Díez‐CampeloUniversidad de Salamanca

Discussion

Loading...

Member takes

Implication

Randomized trial showed encouraging overall survival and progression-free survival in patients with lower-risk myelodysplastic syndromes, indicating imetelstat's treatment potential.

Key Points

  • Overall survival favored imetelstat compared to placebo, showing potential in lower-risk MDS treatment.
  • Randomized controlled trial reported 40% of patients achieved RBC transfusion independence with imetelstat.
  • Analysis utilized Kaplan-Meier methods to explore survival outcomes in key subgroups treated with imetelstat.
  • Findings imply clinical benefits of imetelstat for managing anemia in lower-risk myelodysplastic syndromes.

Cite This Study

Santini et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0b7https://doi.org/10.1182/blood-2025-2074
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study2026 · 1 citations
  2. 2A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study2025 · 1 citations
  3. 3Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 12025 · 4 citations
  4. 4Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis2025 · 2 citations
  5. 5Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial2025